Literature DB >> 22429944

Corticosteroid treatment of idiopathic sudden sensorineural hearing loss: randomized triple-blind placebo-controlled trial.

Ramesh Nosrati-Zarenoe1, Elisabeth Hultcrantz.   

Abstract

OBJECTIVE: To compare the effect of Prednisolone and placebo on the recovery of unilateral idiopathic sudden sensorineural hearing loss. STUDY
DESIGN: Prospective, randomized, triple-blind, placebo-controlled multicenter trial.
SETTING: Four tertiary and 10 secondary referral centers. PATIENTS: Of 103 patients randomly assigned, 93 were included in the modified intention-to-treat analysis. The patients, aged 18 to 80 years, were seeking care within 1 week after onset of acute unilateral sensorineural hearing loss with a mean decrease of 30 dB or greater in the 3 most affected contiguous frequencies. INTERVENTION: Patients were randomly assigned in permuted blocks of 10 to receive Prednisolone or placebo in tapering doses from 60 mg for 3 days and, thereafter, 10 mg less each day until Day 8. If complete recovery, no more medication given, otherwise medication continued at 10 mg per day until Day 30. Final follow-up was after 3 months with audiogram; 47 patients received Prednisolone and 46 placebo. MAIN OUTCOME MEASURE: The primary endpoint was efficacy of treatment on recovery at Day 90. Secondary endpoints were prognostic factors for hearing recovery. Analyses were by modified intention-to-treat and per protocol.
RESULTS: Hearing improvement for 47 Prednisolone-treated patients was 25.5 ± 27.1 dB compared to 26.4 ± 26.2 dB for 46 placebo-treated patients at Day 8 and 39 ± 20.1 dB versus 35.1 ± 38.3 dB after 3 months. Vertigo had significant negative effect on hearing improvement and inflammatory signs in the laboratory workup-a positive prognostic effect, irrespective of treatment.
CONCLUSION: Prednisolone in customary dosage does not seem to influence recovery of idiopathic sudden sensorineural hearing loss.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22429944     DOI: 10.1097/MAO.0b013e31824b78da

Source DB:  PubMed          Journal:  Otol Neurotol        ISSN: 1531-7129            Impact factor:   2.311


  30 in total

1.  Hearing outcome does not depend on the interval of intratympanic steroid administration in idiopathic sudden sensorineural hearing loss.

Authors:  Hideaki Suzuki; Hiroki Koizumi; Jun-Ichi Ohkubo; Nobusuke Hohchi; Shoji Ikezaki; Takuro Kitamura
Journal:  Eur Arch Otorhinolaryngol       Date:  2016-02-15       Impact factor: 2.503

2.  Uni- and multivariate models for investigating potential prognostic factors in idiopathic sudden sensorineural hearing loss.

Authors:  Marco Lionello; Claudia Staffieri; Stefano Breda; Chiara Turato; Luciano Giacomelli; Paola Magnavita; Cosimo de Filippis; Alberto Staffieri; Gino Marioni
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-03-25       Impact factor: 2.503

3.  Fibrinogen is not a prognostic factor for response to HELP-apheresis in sudden sensorineural hearing loss (SSHL).

Authors:  T Berger; T Kaiser; M Scholz; A Bachmann; U Ceglarek; G Hesse; B Hagemeyer; M Stumvoll; J Thiery; A Dietz
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-12-20       Impact factor: 2.503

4.  Corticosteroid treatment of idiopathic sudden sensorineural hearing loss: analysis of an RCT and material drawn from the Swedish national database.

Authors:  Elisabeth Hultcrantz; Ramesh Nosrati-Zarenoe
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-10-29       Impact factor: 2.503

Review 5.  Intratympanic steroid therapy for treatment of idiopathic sudden sensorineural hearing loss.

Authors:  Zachary W Bear; Anthony A Mikulec
Journal:  Mo Med       Date:  2014 Jul-Aug

6.  [Multicenter trial for sudden hearing loss therapy - planning and concept].

Authors:  S K Plontke; M Girndt; C Meisner; R Probst; I Oerlecke; M Richter; J Steighardt; G Dreier; A Weber; I Baumann; S Plößl; J Löhler; R Laszig; J A Werner; T Rahne
Journal:  HNO       Date:  2016-04       Impact factor: 1.284

7.  [A software tool for pure-tone audiometry: Classification of audiograms for inclusion of patients in clinical trials. German version].

Authors:  T Rahne; F Buthut; S Plößl; S K Plontke
Journal:  HNO       Date:  2015-12       Impact factor: 1.284

8.  Hearing Changes After Intratympanic Steroids for Secondary (Salvage) Therapy of Sudden Hearing Loss: A Meta-Analysis Using Mathematical Simulations of Drug Delivery Protocols.

Authors:  Arne Liebau; Olivia Pogorzelski; Alec N Salt; Stefan K Plontke
Journal:  Otol Neurotol       Date:  2018-08       Impact factor: 2.311

9.  The efficacy and safety of systemic injection of Ginkgo biloba extract, EGb761, in idiopathic sudden sensorineural hearing loss: a randomized placebo-controlled clinical trial.

Authors:  Ja-Won Koo; Mun Young Chang; Sung-Cheol Yun; Tae Su Kim; Soo-Keun Kong; Jong Woo Chung; Eui-Kyung Goh
Journal:  Eur Arch Otorhinolaryngol       Date:  2015-11-11       Impact factor: 2.503

10.  Sudden Sensorineural Hearing Loss in Mild COVID-19: Case Series and Analysis of the Literature.

Authors:  Filippo Ricciardiello; Davide Pisani; Pasquale Viola; Elisabetta Cristiano; Alfonso Scarpa; Antonio Giannone; Giuseppe Longo; Giuseppe Russo; Marco Bocchetti; Ciro Coppola; Marco Perrella; Flavia Oliva; Giuseppe Chiarella
Journal:  Audiol Res       Date:  2021-07-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.